[1] Han S, Wang CH, Tong F, et al. Shock index, modified shock index, and age-adjusted shock index in predicting the in-hospital mortality in patients with heart failure and chronic kidney disease. Biomed Environ Sci, 2023; 36, 279−83.
[2] GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet, 2020; 395, 709−33. doi:  10.1016/S0140-6736(20)30045-3
[3] Xue J, Wang YX, Li B, et al. Triglycerides to high-density lipoprotein cholesterol ratio is superior to triglycerides and other lipid ratios as an indicator of increased urinary albumin-to-creatinine ratio in the general population of China: a cross-sectional study. Lipids Health Dis, 2021; 20, 13. doi:  10.1186/s12944-021-01442-8
[4] Zhou MG, Wang HD, Zeng XY, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet, 2019; 394, 1145−58. doi:  10.1016/S0140-6736(19)30427-1
[5] Carriazo S, Ortiz A. European east-west divide in kidney disease: the need to understand the drivers of chronic kidney disease outcomes. Clin Kidney J, 2021; 14, 1−4. doi:  10.1093/ckj/sfaa217
[6] Tang X, Xu L, Meng RG, et al. Association between serum uric acid and the early marker of kidney function decline among Chinese middle-aged and older population: evidence from the China health and retirement longitudinal study. Biomed Environ Sci, 2023; 36, 231−40.
[7] Yang M, Geng CA, Liu XG, et al. Lipid disorders in NAFLD and chronic kidney disease. Biomedicines, 2021; 9, 1405. doi:  10.3390/biomedicines9101405
[8] Opazo-Ríos L, Mas S, Marín-Royo G, et al. Lipotoxicity and diabetic nephropathy: novel mechanistic insights and therapeutic opportunities. Int J Mol Sci, 2020; 21, 2632. doi:  10.3390/ijms21072632
[9] Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol, 2009; 5, 713−21. doi:  10.1038/nrneph.2009.184
[10] Castro BBA, Foresto-Neto O, Saraiva-Camara NO, et al. Renal lipotoxicity: insights from experimental models. Clin Exp Pharmacol Physiol, 2021; 48, 1579−88. doi:  10.1111/1440-1681.13556
[11] Joles JA, Kunter U, Janssen U, et al. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol, 2000; 11, 669−83. doi:  10.1681/ASN.V114669
[12] Wen J, Chen YY, Huang Y, et al. Association of the TG/HDL-C and non-HDL-C/HDL-C ratios with chronic kidney disease in an adult Chinese population. Kidney Blood Press Res, 2017; 42, 1141−54. doi:  10.1159/000485861
[13] Zhang YB, Sheng LT, Wei W, et al. Association of blood lipid profile with incident chronic kidney disease: a Mendelian randomization study. Atherosclerosis, 2020; 300, 19−25. doi:  10.1016/j.atherosclerosis.2020.03.020
[14] Kosugi T, Eriguchi M, Yoshida H, et al. Association between chronic kidney disease and new-onset dyslipidemia: the Japan specific health checkups (J-SHC) study. Atherosclerosis, 2021; 332, 24−32. doi:  10.1016/j.atherosclerosis.2021.08.004
[15] Liu XY, Wu QY, Chen ZH, et al. Elevated triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio increased risk of hyperuricemia: a 4-year cohort study in China. Endocrine, 2020; 68, 71−80. doi:  10.1007/s12020-019-02176-5
[16] Thobani A, Jacobson TA. Dyslipidemia in patients with kidney disease. Cardiol Clin, 2021; 39, 353−363. doi:  10.1016/j.ccl.2021.04.008
[17] Bae JC, Han JM, Kwon S, et al. LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort. Atherosclerosis, 2016; 251, 170−6. doi:  10.1016/j.atherosclerosis.2016.06.029
[18] Liang XD, Ye MY, Tao M, et al. The association between dyslipidemia and the incidence of chronic kidney disease in the general Zhejiang population: a retrospective study. BMC Nephrol, 2020; 21, 252. doi:  10.1186/s12882-020-01907-5
[19] Nam KH, Chang TI, Joo YS, et al. Association between serum high-density lipoprotein cholesterol levels and progression of chronic kidney disease: results from the KNOW-CKD. J Am Heart Assoc, 2019; 8, e011162. doi:  10.1161/JAHA.118.011162
[20] You AJ, Li YX, Tomlinson B, et al. Association between renal dysfunction and low HDL cholesterol among the elderly in China. Front Cardiovasc Med, 2021; 8, 644208. doi:  10.3389/fcvm.2021.644208
[21] Zhang XL, Wang BY, Yang J, et al. Serum lipids and risk of rapid renal function decline in treated hypertensive adults with normal renal function. Am J Hypertens, 2019; 32, 393−401. doi:  10.1093/ajh/hpz001
[22] Wan EYF, Yu EYT, Chin WY, et al. Greater variability in lipid measurements associated with kidney diseases in patients with type 2 diabetes mellitus in a 10-year diabetes cohort study. Sci Rep, 2021; 11, 8047. doi:  10.1038/s41598-021-87067-4
[23] Kim Y, Lee S, Lee Y, et al. Predictive value of triglyceride/high-density lipoprotein cholesterol for major clinical outcomes in advanced chronic kidney disease: a nationwide population-based study. Clin Kidney J, 2021; 14, 1961−8. doi:  10.1093/ckj/sfaa252
[24] Bai YN, Yang AM, Pu HQ, et al. Cohort profile: the China metal-exposed workers cohort study (Jinchang Cohort). Int J Epidemiol, 2017; 46, 1095−6e.
[25] Wang SS, Lay S, Yu HN, et al. Dietary guidelines for Chinese residents (2016): comments and comparisons. J Zhejiang Univ Sci B, 2016; 17, 649−56. doi:  10.1631/jzus.B1600341
[26] Writing Group of 2010 Chinese Guidelines for the Management of Hypertension. 2010 Chinese guidelines for the management of hypertension. Am J Hypertens, 2012; 25, 271. doi:  10.1038/ajh.2011.248
[27] Chinese Diabetes Society. Guidelines for the prevention and control of type 2 diabetes in China (2017 edition). Chin J Pract Intern Med, 2018; 38, 292−344. (In Chinese)
[28] Joint Committee for Guideline Revision. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol, 2018; 15, 1−29.
[29] Expert Group on Early Detection, Diagnosis and Treatment System Construction of Chronic Kidney Disease in Shanghai. Guideline for screening, diagnosis, prevention and treatment of chronic kidney disease. Chin J Pract Intern Med, 2017; 37, 28−34. (In Chinese)
[30] Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis, 2014; 63, 713−35. doi:  10.1053/j.ajkd.2014.01.416
[31] Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med, 2009; 150, 604−12. doi:  10.7326/0003-4819-150-9-200905050-00006
[32] Swartling O, Rydell H, Stendahl M, et al. CKD progression and mortality among men and women: a nationwide study in Sweden. Am J Kidney Dis, 2021; 78, 190-9. e1.
[33] Mozafari AA, Mansournia MA, Sayehmiri K, et al. Effect of lipid abnormality on CKD progression from moderate to severe stage: application of flexible parametric proportional-hazards and proportional-odds models. Iran Red Crescent Med J, 2020; 22, e102507.
[34] Pei K, Gui T, Li C, et al. Recent progress on lipid intake and chronic kidney disease. Biomed Res Int, 2020; 2020, 3680397.
[35] Kawachi K, Kataoka H, Manabe S, et al. Low HDL cholesterol as a predictor of chronic kidney disease progression: a cross-classification approach and matched cohort analysis. Heart Vessels, 2019; 34, 1440−55. doi:  10.1007/s00380-019-01375-4
[36] Tsuruya K, Yoshida H, Nagata M, et al. Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population. Am J Kidney Dis, 2015; 66, 972−83. doi:  10.1053/j.ajkd.2015.05.011
[37] Li W, Du ZJ, Wei HL, et al. Total cholesterol to high-density lipoprotein cholesterol ratio is independently associated with CKD progression. Int Urol Nephrol, 2022; 54, 2057−63. doi:  10.1007/s11255-021-03099-9
[38] McPherson R, Frohlich J, Fodor G, et al. Canadian cardiovascular society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol, 2006; 22, 913−27. doi:  10.1016/S0828-282X(06)70310-5
[39] Chabowski DS, Cohen KE, Abu-Hatoum O, et al. Crossing signals: bioactive lipids in the microvasculature. Am J Physiol Heart Circ Physiol, 2020; 318, H1185−97. doi:  10.1152/ajpheart.00706.2019
[40] Wu Y, Chen Y, Chen D, et al. Presence of foam cells in kidney interstitium is associated with progression of renal injury in patients with glomerular diseases. Nephron Clin Pract, 2009; 113, c155−61. doi:  10.1159/000232596
[41] Gai ZB, Wang TQ, Visentin M, et al. Lipid accumulation and chronic kidney disease. Nutrients, 2019; 11, 722. doi:  10.3390/nu11040722
[42] Merscher S, Pedigo CE, Mendez AJ. Metabolism, energetics, and lipid biology in the podocyte - cellular cholesterol-mediated glomerular injury. Front Endocrinol, 2014; 5, 169.
[43] Kang HT, Shim JY, Lee YJ, et al. Association between the ratio of triglycerides to high-density lipoprotein cholesterol and chronic kidney disease in Korean adults: the 2005 Korean national health and nutrition examination survey. Kidney Blood Press Res, 2011; 34, 173−9. doi:  10.1159/000323895
[44] Bulbul MC, Dagel T, Afsar B, et al. Disorders of lipid metabolism in chronic kidney disease. Blood Purif, 2018; 46, 144−52. doi:  10.1159/000488816
[45] Goonasekera MA, Mafham MM, Haynes RJ. LDL-cholesterol reduction in chronic kidney disease: options beyond statins. Curr Opin Nephrol Hypertens, 2020; 29, 480−8. doi:  10.1097/MNH.0000000000000628
[46] Sanguankeo A, Upala S, Cheungpasitporn W, et al. Effects of statins on renal outcome in chronic kidney disease patients: a systematic review and meta-analysis. PLoS One, 2015; 10, e0132970. doi:  10.1371/journal.pone.0132970
[47] Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci, 2021; 17, 1447−547. doi:  10.5114/aoms/141941